A review of the use of exemestane in early breast cancer.

Ther Clin Risk Manag · 2009 · PMC2697518 · PMID 19436613

Europe PMC

hedged sentence

0.1600

closest p · 3.2× alpha

0.1600

boldest claim

The sentences

did not reach statistical significancep = 0.16not close (p > 0.1)

These differences did not reach statistical significance (p = 0.16 and p = 0.17 respectively). 12 It can be concluded from this study, that at least as far as 5 years from switching to exemestane, there was no statistically significant detriment in terms of cardiovascular events by using the steroidal aromatase inactivator exemestane.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.